[05 April 2013]
Products Affected - Description
RabAvert (NDC 63851-0501-01), Novartis
Imovax (NDC 49281-0250-51), Sanofi-Pasteur
Reason for the Shortage
- Sanofi Pasteur states the reason for the shortage is increased demand and manufacturing delay.
- Novartis could not provide a reason for this shortage.
No presentations are fully available.
Estimated Resupply Dates
- Novartis has RabAvert available for post-exposure use only. Contact Novartis to order RabAvert for post-exposure use. RabAvert may still be available from wholesalers.
- Sanofi-Pasteur has a limited supply of Imovax available. Sanofi-Pasteur is releasing this product for post-exposure emergency use only. The company could not estimate when Imovax would be readily available again.
April 5, 2013; March 6, 2013; February 20, 2013; January 23, 2013; December 10, 2012; November 13, 2012; October 24, 2012; September 28, 2012; September 5, 2012, University of Utah, Drug Information Service. Copyright 2013, Drug Information Service, University of Utah, Salt Lake City, UT.
This information is provided through the support of Novation to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Novation, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Novation, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Novation, ASHP nor University of Utah endorses or recommends the use of any drug.
« Back to Drug Shortage Product Bulletins